반응식
[N:1]1([CH2:7][CH2:8][OH:9])[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1.F[C:11]1[CH:20]=[C:19]2[C:14]([CH:15]=[C:16]([NH:25][C:26]3[CH:30]=[C:29]([CH3:31])[NH:28][N:27]=3)[N:17]=[C:18]2[O:21][CH:22]([CH3:24])[CH3:23])=[CH:13][C:12]=1[O:32][CH3:33]>>[CH:22]([O:21][C:18]1[C:19]2[C:14](=[CH:13][C:12]([O:32][CH3:33])=[C:11]([O:9][CH2:8][CH2:7][N:1]3[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]3)[CH:20]=2)[CH:15]=[C:16]([NH:25][C:26]2[CH:30]=[C:29]([CH3:31])[NH:28][N:27]=2)[N:17]=1)([CH3:24])[CH3:23]참가 물질
3
실험 절차
Similar procedure as described in example 378 was used, starting from 2-Piperidin-1-yl-ethanol and (7-Fluoro-1-isopropoxy-6-methoxy-isoquinolin-3-yl)-(5-methyl-1H-pyrazol-3-yl)-amine to give [1-Isopropoxy-6-methoxy-7-(2-piperidin-1-yl-ethoxy)-isoquinolin-3-yl]-(5-methyl-1H-pyrazol-3-yl)-amine. LC-MS: m/e 440(MH+).
출처 및 근거
- ORD 기록
- ord-121b4e70f7cf461fafd81d007f61d188
- 출처 데이터셋
- uspto-grants-2009_08
- 특허 번호
- US07572809B2
연결된 노트
불러오는 중…